BergasaNVJonesEA. The pruritus of cholestasis. Semin Liver Dis1993;13:319–27.
2.
JonesEABergasaNV. The pruritus of cholestasis and the opioid system. JAMA1992;268:3359–62.
3.
GardenJMOstrowDRoenigkHH. Pruritus in hepatic cholestasis. Arch Dermatol1985;121:1415–20.
4.
JonesEABergasaNV. The pruritus of cholestasis: From bile acids to opiate agonists. Hepatology1990;11:854–87.
5.
SchoenfieldLJSjovallJPermanE. Bile acids on the skin of patients with pruritic hepatobiliary disease. Nature1967;213:93–4.
6.
Van ItallieTBHashimSACramptonRSTennentDM. The treatment of pruritus and hypercholesterolemia of primary biliary cirrhosis with cholestyramine. N Engl J Med1961;265:469–74.
7.
GhentCNBloomerJRHsiaYE. Efficacy and safety of long-term treatment of familial intrahepatic cholestatsis with phenobarbital. J Pediatr1978;93:127–32.
8.
MurphyGMRossABillingBH. Serum bile acids in primary biliary cirrhosis. Gut1972;13:201–6.
9.
GaleazziR. Rifampicin induced elevation in serum bile acids in man. Dig Dis Sci1980;25:108–12.
10.
StiehlAThalerMMAdmiranoWH. The effects of phenobarbital on bile salts and bilirubin in patients with intrahepatic and extrahepatic cholestasis. N Engl J Med1972;286:858–61.
11.
CynamonHAAndresJMIafrateRP. Rifampin relieves pruritus in children with cholestatic liver disease. Gastroenterology1990;98:1013–6.
12.
HeumanDM. Hepatoprotective properties of ursodeoxycholic acid. Gastroenterology1993;104:1865–70.
13.
HanidMALeviAJ. Phototherapy for pruritus in primary biliary cirrhosis (letter). Lancet1980;2:530.
14.
LauterburgBHPinedaAABurgstalerEATaswellHFDicksonERCarlsonGL. Treatment of pruritus of cholestasis by plasma perfusion through USP-charcoal-coated glass beads. Lancet1980;2:53–5.
15.
BergasaNVJonesEA. The pruritus of cholestasis: Potential pathogenic and therapeutic implications of opioids. Gastroenterology1995;108: 1582–8.
16.
BergasaNVJonesEA. Management of the pruritus of cholestasis: Potential role of opiate antagonists. Am J Gastroenterol1991;86:1404–12.
17.
CasaleTBBowmanSKalinerM. Induction of human cutaneous mast cell degranulation by opiates and endogenous opioid peptides: Evidence for opiate and non-opiate receptor participation. J Allergy Clin Immunol1984;73:775–81.
18.
LaidlawJReadAESherlockS. Morphine tolerance in hepatic cirrhosis. Gastroenterology1961;40:389–96.
19.
ThorntonJRLosowskyMS. Plasma leucine enkephalin is increased in liver disease (abstract). Gut1988;29:A1429.
20.
ThorntonJRLosowskyMS. Opioid peptides and primary biliary cirrhosis. Br Med J1988;297:1501–4.
21.
BernsteinJESwiftR. Relief of intractable pruritus with naloxone. Arch Dermatol1979;115:1366–7.
22.
GalTJDiFazioCADixonR. Prolonged blockade of opioid effect with oral nalmefene. Clin Pharmacol Ther1986;40:537–42.
23.
BergasaNVAllingDWTalbotTLSchmittJPSwainMGFongTLRelief from the intractable pruritus of chronic cholestasis associated with oral nalmefene therapy (abstract). Hepatology1993;18:154A.
24.
BergasaNVAllingDWTalbotTLChiaSCSouppayaMConjeevbaramHNalmefene therapy is associated with the relief of the pruritus of cholestasis: Results of a double-blind randomized placebo-controlled trial (abstract). Hepatology1993;18:177A.
25.
BergasaNVAllingDWTalbotTLSwainMGYurdaydinCTurnerMLEffects of naloxone infusions in patients with the pruritus of cholestasis. Ann Intern Med1995;123:161–7.
26.
CarsonKLTranTTCottonPShararaAIHuntC. Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease. Am J Gastroenterol1996;91:1022–3.
27.
MorhganCJKostenTR. Potential toxicities of high doses of naltrexone in patients with appetite disorders. In: ReidLD, ed. Opioids, bulimia, and alcohol abuse and alcoholism. New York: Springer-Verlag, 1990:261–80.
28.
AllenJIMitchellJKnopmanDLevineSMorleyJE. High-dose naltrexone and hepatic enzyme abnormalities (abstract). Gastroenterology1985;88:A1646.
29.
WolfhagenFHJSternieriEHopWCJVitaleGBertolottiMBuurenHRV. Oral naltrexone treatment for cholestatic pruritus: A double-blind, placebo-controlled study. Gastroenterology1997;113:1264–9.
